ATE459004T1 - Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung - Google Patents

Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung

Info

Publication number
ATE459004T1
ATE459004T1 AT05010407T AT05010407T ATE459004T1 AT E459004 T1 ATE459004 T1 AT E459004T1 AT 05010407 T AT05010407 T AT 05010407T AT 05010407 T AT05010407 T AT 05010407T AT E459004 T1 ATE459004 T1 AT E459004T1
Authority
AT
Austria
Prior art keywords
receptor
protein
fprl2
ligand
application
Prior art date
Application number
AT05010407T
Other languages
English (en)
Inventor
Isabelle Migeotte
Marc Parmentier
David Communi
Maryse Brait
Original Assignee
Euroscreen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroscreen Sa filed Critical Euroscreen Sa
Application granted granted Critical
Publication of ATE459004T1 publication Critical patent/ATE459004T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05010407T 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung ATE459004T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04447122 2004-05-14
EP04447231 2004-10-18

Publications (1)

Publication Number Publication Date
ATE459004T1 true ATE459004T1 (de) 2010-03-15

Family

ID=34982585

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08159325T ATE496304T1 (de) 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen-2 (fprl2) g protein gekoppelten rezeptor
AT05010407T ATE459004T1 (de) 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08159325T ATE496304T1 (de) 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen-2 (fprl2) g protein gekoppelten rezeptor

Country Status (7)

Country Link
US (3) US7582416B2 (de)
EP (2) EP2020604B1 (de)
JP (2) JP4694887B2 (de)
AT (2) ATE496304T1 (de)
CA (2) CA2810292C (de)
DE (2) DE602005026072D1 (de)
DK (2) DK2020604T3 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1123401A1 (de) * 1998-10-22 2001-08-16 The General Hospital Corporation Bioaktive peptide und peptid-derivate von parathyroidhormon (pth) und parathyroidhormon verwandte peptide (pthrp)
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
CA2454275C (en) * 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
EP1610813A4 (de) * 2003-03-19 2009-07-01 Gen Hospital Corp KONFORMATIONSEINGESCHRÄNKTE PARATHORMONE MIT a-HELIX-STABILISATOREN
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
CA2810292C (en) * 2004-05-14 2015-09-29 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof
EP2054077A4 (de) * 2006-08-04 2010-10-13 Gen Hospital Corp Polypeptidderivate des parathyroidhormons (pth)
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
WO2008156858A2 (en) * 2007-06-20 2008-12-24 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
EP2187902B1 (de) * 2007-08-01 2013-04-17 The General Hospital Corporation Screeningverfahren mit g-protein-gekoppelten rezeptoren und entsprechende zusammensetzungen
WO2010063652A1 (en) * 2008-12-04 2010-06-10 Sanofi-Aventis Methods and uses involving heme binding protein 1
ES2431298T3 (es) 2009-05-18 2013-11-25 Actelion Pharmaceuticals Ltd. Derivados de espiro[2.4]heptano puenteados como agonistas del receptor de ALX y/o FPRL2
WO2011073918A2 (en) 2009-12-16 2011-06-23 Actelion Pharmaceuticals Ltd Peptides as modulators of fprl1 and/or fprl2
RU2604809C2 (ru) 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
EP3314255B1 (de) * 2015-06-25 2019-07-31 H. Hoffnabb-La Roche Ag Zellbasierter assay zur bestimmung von antikörpern oder ligandenbindung und funktion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919649A (en) 1988-11-18 1999-07-06 The General Hospital Corporation Camp-responsive transcriptional enhancer binding protein
EP0605522B1 (de) 1991-09-23 1999-06-23 Medical Research Council Methoden zur Herstellung humanisierter Antikörper
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7119190B2 (en) * 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
US6872538B1 (en) 1998-07-06 2005-03-29 Euroscreen S.A. High-throughput screening diagnostic and/or dosage method of an agonist and/or an antagonist for a calcium-coupled receptor
AU7494200A (en) * 1999-09-15 2001-04-17 Incyte Genomics, Inc. Proteins associated with cell differentiation
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP4184875B2 (ja) * 2002-06-14 2008-11-19 武田薬品工業株式会社 新規スクリーニング方法
CA2810292C (en) * 2004-05-14 2015-09-29 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof

Also Published As

Publication number Publication date
CA2810292C (en) 2015-09-29
US20090053739A1 (en) 2009-02-26
EP1607745A2 (de) 2005-12-21
CA2504920C (en) 2014-04-01
CA2810292A1 (en) 2005-11-14
JP5314061B2 (ja) 2013-10-16
US7842795B2 (en) 2010-11-30
US7659251B2 (en) 2010-02-09
US20100009406A1 (en) 2010-01-14
CA2504920A1 (en) 2005-11-14
JP4694887B2 (ja) 2011-06-08
DE602005019495D1 (de) 2010-04-08
EP1607745B1 (de) 2010-02-24
EP1607745A3 (de) 2006-07-26
EP2020604B1 (de) 2011-01-19
DK2020604T3 (da) 2011-05-16
JP2006025787A (ja) 2006-02-02
ATE496304T1 (de) 2011-02-15
DE602005026072D1 (de) 2011-03-03
JP2011078437A (ja) 2011-04-21
EP2020604A1 (de) 2009-02-04
DK1607745T3 (da) 2010-06-14
US20060078559A1 (en) 2006-04-13
US7582416B2 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
GEP20094629B (en) Nogo receptor binding protein
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
CY1109725T1 (el) Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
ATE504599T1 (de) Zur aktivierung von rezeptoren fähige fusionspolypeptide
WO2005087811A3 (en) Estrogen receptors and methods of use
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
EP3300739A3 (de) An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
WO2004090103A8 (en) Identification of novel nogo-receptors and methods related thereto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties